Role of cytochrome P4502B6 in methadone metabolism and clearance

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 305-313

  Kharasch, Evan D ^a   Stubbert, Kristi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alfentanil; CYP2B6; CYP3A; Cytochrome P450 2B6; Cytochrome P450 3A; Methadone

Indexed keywords

ALFENTANIL; CYTOCHROME P450 2B6; METHADONE; TICLOPIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; ARYL HYDROCARBON HYDROXYLASES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; TICLOPIDINE; YOUNG ADULT;

EID: 84875845231     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.1     Document Type: Article

References (42)

1. Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction-A clinical perspective. Eur J Clin Pharmacol. 2010;66:537-545.
2. Kharasch ED. Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? Anesth Analg. 2011;112:13-16.
3. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev. 2007; CD003971.
4. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
5. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153-1193.
6. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition and miotic effects of methadone. Clin Pharmacol Ther. 2004;76:250-269.
7. Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA. Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos. 2010;38:1308-1313.
8. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9:365-373.
9. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of La-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos. 1997;25:1347-1353.
10. ShiranMR, LennardMS, IqbalMZ, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2009;67:29-37.
11. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19:4-16.
12. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse. 2011;37:1-11.
13. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS. 2005;19:1635-1641.
14. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics. I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008;84:497-505.
15. Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009;101:158-168.
16. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009;110:660-672.
17. Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 2012;116:432-447.
18. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16:36-44.
19. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321:389-399.
20. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108:363-374.
21. Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol. 2010;108:55-62.
22. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008;52:1663-1669.
23. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668-681.
24. Wang SC, Ho IK, Tsou HH, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone Senantiomer. J Clin Psychopharmacol. 2011;31:463-469.
25. Kharasch E, Whittington D, Ensign D, et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2012;91:673-684.
26. Richter T, Murdter TE, Heinkele G, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004;308:189-197.
27. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77:553-559.
28. Whittington D, Sheffels P, Kharasch ED. Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. J Chrom B. 2004;809:313-321.
29. Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007;82:410-426.
30. Ha-Duong N-T, Dijols S, Macherey A-C, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry. 2001;40:12112-12122.
31. Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol. 2005;45:1187-1197.
32. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steadystate pharmacokinetics of (R)-and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000;50:427-440.
33. Peltoniemi MA, Saari TI, Hagelberg NM, et al. Exposure to oral Sketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011;90:296-302.
34. Bae JW, Jang CG, Lee SY. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol. 2011;51:1704-1711.
35. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999;47:403-412.
36. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos. 2001;29:1123-1129.
37. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 2012 in press.
38. Fonseca F, de la Torre R, Diaz L, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS ONE. 2011;6:e19527.
39. Lötsch J, Skarke C, Wieting J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79:72-89.
40. Sims SA, Snow LA, Porucznik CA. Surveillance of methadonerelated adverse drug events using multiple public health data sources. J Biomed Inform. 2007;40:382-389.
41. Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharm Ther. 1975;18:180-190.
42. Änggärd E, Nilsson MI, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state. Eur J Clin Pharmacol. 1979;16:53-57.